Lymphoma Remission, Cure, and Relapse

Treatment for lymphoma often takes months to complete. At the end of this ordeal, you want to know where you stand. Are you cured? Why do some lymph nodes still feel enlarged? Is your disease still there? Can it come back again? Healthcare providers try to explain the situation by using such terms as "remission," "relapse," and "cure," but what do they really mean?

Doctor talking to patient in doctor's office
Blend Images / Jon Feingersh / Vetta / Getty Images

Your First Follow-up Visit

The day you receive your last treatment is not the day that the healthcare provider will assess you for a response. That is because cancer treatments often take some time to act. Usually, your healthcare provider will call you in for a check-up after 4 to 8 weeks. This gives the therapy some time to complete its action on cancer. The practitioner then does some tests to evaluate you for remission.

Understanding Remission

Remission means that your lymphoma has been either eliminated or reduced. When the tumor is completely gone, healthcare providers call it "complete remission." When the tumor has been largely reduced but it still remains, it is called "partial remission." For Hodgkin lymphoma and aggressive non-Hodgkin lymphoma (NHL), healthcare providers always aim for a complete remission. For indolent or low-grade NHL — which tends to grow or progress more slowly — often a partial remission will suffice.

Remission Versus Cure

Even if your disease is eliminated after treatment is over, it is still not called a cure. Lymphomas have a chance of recurring, and the healthcare provider will often wait for a few years before he is confident that your disease will not return. In Hodgkin lymphoma, for instance, PET/CT can help detect any disease that remains after treatment. This can be helpful, for example, when there is a residual mass or enlargement in the chest and it is not clear whether it reflects scarring or active disease.

Only after that can he tell you that you are cured. For Hodgkin and aggressive non-Hodgkin lymphomas, the disease has the highest chance of returning within a couple of years. Indolent NHL can often return after many years.

Regular Follow-Up Visits

Regular visits to the healthcare provider are the best way to keep tabs on your disease. The healthcare provider will examine you at each visit. He may also order some tests and scans. Early detection of the return of your disease can often result in better outcomes with subsequent treatments. If no disease is found, you can be reassured about your health.

Disease Relapse

Lymphomas may come back, or relapse, after having been eliminated initially. This happens only in a minority of people. When it does, it can still be well controlled with subsequent treatment. Relapse can occur in the same areas that were previously involved, or it can occur in new areas of the body. You should report any new swellings or health problems to your oncologist.

Managing Your Worries

Complete remission after treatment is a very good sign. Most individuals remain free of disease. Putting off visits in fear of relapse is a completely human response and very understandable, since dealing with this possibility is never a welcomed part of the journey. But do not delay seeing your healthcare provider. These visits give you a chance to speak to the practitioner and clarify your doubts. Even if a relapse occurs, don't panic. There are several effective treatments available to control your disease.​

Was this page helpful?
4 Sources
Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read our editorial process to learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.
  1. Lymphoma Action. Follow-up appointments.

  2. Lymphoma Action. Treatment and remission.

  3. Lymphoma Action. What happens if lymphoma relapses?.

  4. Lingohr-Smith M, Aurora B, Lin J, Menges B, Makenbaeva D. Prevalence of Hodgkin lymphoma and relapsed or refractory Hodgkin lymphoma in the US. Journal of Clinical Oncology. 2016;34(15 suppl):e19020-e19020.

Additional Reading